Scans

Tools

Home

Charts

Watchlist

Products

Camlin Fine Sciences Ltd

CAMLINFINE

NSE

₹91.61-3.66%19 Oct 2026 at 3:57 PM

Reports

Chemicals Others

Camlin Fine Sciences Ltd

CAMLINFINE

NSE

₹91.61

-3.66%

19 Oct 2026 at 3:57 PM

SOICxStockScans Reports

Ask AI

Chemicals Others

Indices

Business Overview: What the company does, in plain English.Growth Catalysts: The forward growth drivers and triggers.Guidance Report: Management guidance vs outcomes.Forensic Report: Accounting quality and red flags.Deep Dive Report: In-depth business analysis.

Camlin Fine Sciences is a specialty-chemical company built on a single, recurring idea: own the molecule from raw material to finished solution, then move closer to the customer’s recipe. It began in the 1990s as an antioxidant unit of an Indian stationery company, but the business transformed in 2012 when it bought an Italian plant that made Hydroquinone and Catechol - the two building blocks of its entire product chain - giving it captive control of inputs that rivals have to buy. Over the last three years, the company has deliberately shifted from selling single-molecule “straight” chemicals toward custom-formulated “blends” - mixtures tailored to a specific customer’s shelf-life or performance problem - which makes the relationship stickier and the business harder to undercut on price.

Business segments

Three engines built on the same diphenol backbone - a shelf-life solutions business that is the group’s commercial heart, an aroma-ingredients plant that turns captive catechol into vanillin, and a performance-chemicals unit that supplies the industrial world while feeding the other two.

1. Shelf-life solutions and blends: the group’s commercial engine

This is where the company makes most of its money - not by selling commodity antioxidant molecules, but by formulating over 200 custom blends that keep food, pet food and feed fresh longer, and those blends now account for three-quarters of the segment.

Custom recipes, not just molecules - the company takes its own antioxidant straights (TBHQ, BHA and Ascorbyl Palmitate) and combines them with natural extracts like rosemary, green tea and mixed tocopherols into more than 200 tailored formulations, each designed for a specific customer’s oil stability, feed preservation or clean-label requirement. That turns a commodity input into a high-value solution the customer is reluctant to switch.
Dominant in the base molecules - CFS holds over 50% of the global market for TBHQ and BHA, the single-molecule antioxidants that are the raw material for its own blends and that it still sells as straights to industries from edible oils to biodiesel. When straight-molecule prices come under pressure from local competitors, the company deliberately channels that volume into its own blends rather than fighting on price.
Pet food is the biggest plate - in FY2024-25, pet food contributed more than 55% of the segment’s revenue, with North America leading the growth, reflecting a customer base of large multinationals and regional manufacturers that need antioxidants to stop fats going rancid in dry and wet pet food.
A lab on every continent - six application laboratories in Italy, India, the US, Mexico, Belgium and Brazil develop custom blends, run stability studies and provide technical support directly to customers, which is how a chemical company builds relationships that last. Manufacturing for blends happens at facilities in India, Brazil, Mexico and Belgium, plus a contract arrangement in the US.
Moving into how food feels - the newest products are emulsifier-based ingredients that improve texture, mouthfeel and process efficiency for bakeries, chocolate makers and confectioners, sold under the Ezential brand alongside the natural-antioxidant NaSure range.

2. Aroma ingredients: vanillin from the group’s own catechol

CFS is the only India-based producer of vanillin and ethyl vanillin, made in a fully integrated plant where the raw material catechol comes from the group’s own diphenol facility - and anti-dumping duties on Chinese rivals are reshaping the market in its favour.

Ethyl vanillin is the pivot - in early 2026, the company stopped methyl vanillin production and converted the plant to ethyl vanillin, which is three times more potent and commands a higher price. Orders on hand for the next quarter were roughly 300 metric tons, with a production campaign of about 600 metric tons planned, and average realisations rose from below $11 to above $12.50 per kilogram.
Tariffs are a tailwind - Chinese producers have used predatory pricing and dumping, which led the US and European Union to levy anti-dumping duties on Chinese vanillin, benefiting CFS as the only non-Chinese manufacturer at scale. The company still faces a 15% tariff on its own vanillin in those markets, and has managed inventory timing to reduce the impact.
The China JV is being wound down - CFS’s former vanillin plant in China, operated through a joint venture, has been shut since February 2021 due to a legal dispute over intellectual property, and the board approved its liquidation in May 2025, removing a distraction and a source of legal risk.

3. Performance chemicals: the diphenol backbone and its industrial derivatives

This engine makes the two diphenols - hydroquinone and catechol - that feed the group’s own vanillin and antioxidant businesses, while also selling derivatives into petrochemicals, agrochemicals and pharmaceuticals, though the manufacturing model is being restructured under cost pressure.

Two molecules, one reaction - phenol is converted into hydroquinone and catechol as joint products in a roughly 40-45% to 55% ratio, meaning you cannot make one without the other. That joint-production reality is why the group’s vertical integration matters: catechol goes into vanillin, hydroquinone derivatives go into antioxidants like TBHQ, and the surplus is sold externally.
Dahej replaced Italy - the greenfield diphenol plant at Dahej, commissioned in 2020, was built to produce at a much lower cost than the legacy Italian facility, using a lean workforce of around 70 people and a heat-conservation system that cuts raw-material consumption and carbon footprint. Capacity was expanded from 10,000 to 15,000 tonnes per year through a de-bottlenecking exercise completed in 2022, funded entirely from internal cash.
The Italian subsidiary is in liquidation - the Ravenna diphenol facility ceased operations in August 2023 after a steep decline in prices and demand, was deemed economically unviable, and judicial liquidation proceedings were initiated for CFS Europe S.p.A. in March 2026. The blending business in Italy continues separately.
Even Dahej is under review - by early 2026, with phenol raw-material costs having jumped from INR 85 to INR 150 per kilogram and catechol in global oversupply selling below production cost, the company cut diphenol manufacturing at Dahej to reduce cash burn, choosing instead to import hydroquinone from China and draw down existing catechol stock that covers 8-9 months of vanillin production.
Derivatives reach industrial customers - the downstream portfolio includes MEHQ, HQEE, Chloranil and Guaiacol, sold into polymers, agrochemicals, pharmaceuticals and printing inks, and the company holds a long-term preferred supply agreement with Lockheed Martin for a catechol derivative used in flow-battery energy storage.

Group structure and partners

A global network of manufacturing and sales subsidiaries across Europe, the Americas and Asia, with two major operations now in liquidation and a fresh acquisition in France adding natural-ingredient technology.

European footprint in transition - the Italian diphenol subsidiary CFS Europe is in judicial liquidation, while the recently acquired Belgian company Vitafor (bought for €1 in 2024) manufactures feed ingredients and nutritional products near the Port of Antwerp, contributing ₹8,488 lakh in revenue in FY2024-25. Vinpai, the French functional-ingredients company listed on Euronext Growth, became an 83.82% subsidiary in January 2026, bringing over 3,500 formulas based on algae, plants and minerals and serving customers in more than 36 countries.
Americas built through acquisition - Dresen Quimica in Mexico, now wholly owned through CFS Mexico after a merger in 2025, manufactures and distributes specialty chemical solutions across North, Central and South America with its own sales force and subsidiaries in Peru, Colombia, Guatemala and the Dominican Republic. CFS do Brasil operates a 6,000-tonne blending plant and handles distribution of bulk antioxidants and vanillin in South America.
Asia anchored by India and a discontinued China JV - the vanillin joint venture in Ningbo, China, is in liquidation with retrospective effect from December 31, 2024, while the 80%-owned AlgalR NutraPharms in India produces algal Omega-3 fatty acids under the BioSus brand using proprietary fermentation technology. Chemolutions Chemicals, a 94% subsidiary, does contract manufacturing for CFS at Tarapur.
One strategic customer of note - the long-term preferred supply agreement with Lockheed Martin for a catechol derivative used in flow batteries is a small but distinctive validation of the group’s chemistry capabilities in advanced energy storage.

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹1,751Cr

Close Price

₹91.14

Industry

Chemicals Others

Price To Earnings

—

Price To Sales

0.95

Revenue

₹1,845Cr

Rev Gr TTM

Revenue Growth TTM

9.33%

PAT Gr TTM

PAT Growth TTM

100.45%

Consolidated

Standalone

Numbers

Percentage

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	406	386	377	381	417	431	432	408	460	441	425	520
Growth YoY Revenue Growth YoY%	-16.0	-0.5	-11.7	-9.2	2.8	11.7	14.6	7.1	10.2	2.2	-1.6	27.5
Expenses ExpensesCr	381	363	345	352	366	373	370	387	426	419	404	511
Operating Profit Operating ProfitCr	25	23	31	29	51	58	62	20	33	21	21	9
OPM OPM%	6.2	6.0	8.4	7.6	12.3	13.4	14.4	5.0	7.3	4.8	5.0	1.8
Other Income Other IncomeCr	2	2	6	2	8	-1	7	8	4	-15	17	-8
Interest Expense Interest ExpenseCr	20	14	16	23	26	34	15	15	19	17	23	14
Depreciation DepreciationCr	19	21	13	15	17	14	17	16	19	16	21	19
PBT PBTCr	-12	-10	8	-7	16	9	37	-3	0	-28	-5	-32
Tax TaxCr	9	5	-12	11	-26	7	8	0	6	0	-6	0
PAT PATCr	-21	-14	-82	-35	-116	-7	0	-11	-15	-37	86	-34
Growth YoY PAT Growth YoY%	-311.0	-162.5	-2,450.3	-388.3	-457.4	47.7	100.1	69.2	87.1	-396.6	78,336.4	-214.8
NPM NPM%	-5.1	-3.7	-21.7	-9.1	-27.8	-1.7	0.0	-2.6	-3.3	-8.4	20.3	-6.5
EPS EPS₹	-1.1	-0.7	-4.5	-1.9	-5.7	-0.7	-1.3	-0.5	-0.8	-2.4	4.6	-1.6

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	406	386	377	381	417	431	432	408	460	441	425	520
Growth YoY Revenue Growth YoY%	-16.0	-0.5	-11.7	-9.2	2.8	11.7	14.6	7.1	10.2	2.2	-1.6	27.5
Expenses ExpensesCr	381	363	345	352	366	373	370	387	426	419	404	511
Operating Profit Operating ProfitCr	25	23	31	29	51	58	62	20	33	21	21	9
OPM OPM%	6.2	6.0	8.4	7.6	12.3	13.4	14.4	5.0	7.3	4.8	5.0	1.8
Other Income Other IncomeCr	2	2	6	2	8	-1	7	8	4	-15	17	-8
Interest Expense Interest ExpenseCr	20	14	16	23	26	34	15	15	19	17	23	14
Depreciation DepreciationCr	19	21	13	15	17	14	17	16	19	16	21	19
PBT PBTCr	-12	-10	8	-7	16	9	37	-3	0	-28	-5	-32
Tax TaxCr	9	5	-12	11	-26	7	8	0	6	0	-6	0
PAT PATCr	-21	-14	-82	-35	-116	-7	0	-11	-15	-37	86	-34
Growth YoY PAT Growth YoY%	-311.0	-162.5	-2,450.3	-388.3	-457.4	47.7	100.1	69.2	87.1	-396.6	78,336.4	-214.8
NPM NPM%	-5.1	-3.7	-21.7	-9.1	-27.8	-1.7	0.0	-2.6	-3.3	-8.4	20.3	-6.5
EPS EPS₹	-1.1	-0.7	-4.5	-1.9	-5.7	-0.7	-1.3	-0.5	-0.8	-2.4	4.6	-1.6

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	489	534	721	892	1,049	1,187	1,412	1,682	1,613	1,629	1,723	1,845
Growth Revenue Growth%	-12.3	9.1	35.0	23.8	17.6	13.2	18.9	19.1	-4.1	1.0	5.8	9.3
Expenses ExpensesCr	398	506	708	824	918	1,005	1,259	1,476	1,539	1,413	1,616	1,760
Operating Profit Operating ProfitCr	92	28	13	69	131	182	153	205	74	216	107	85
OPM OPM%	18.8	5.3	1.7	7.7	12.5	15.3	10.8	12.2	4.6	13.3	6.2	4.6
Other Income Other IncomeCr	0	15	12	14	3	5	33	-4	-34	6	5	-2
Interest Expense Interest ExpenseCr	24	27	28	37	43	38	36	59	60	96	73	73
Depreciation DepreciationCr	17	22	27	29	33	44	56	63	79	61	71	75
PBT PBTCr	50	-6	-31	17	58	105	94	80	-99	65	-32	-65
Tax TaxCr	14	-2	-7	14	28	40	34	41	6	-1	0	-1
PAT PATCr	36	-4	-24	3	30	65	60	40	-105	65	-32	1
Growth PAT Growth%	-34.9	-112.4	-440.0	112.5	892.4	119.1	-7.6	-34.1	-363.4	162.1	-148.4	100.5
NPM NPM%	7.3	-0.8	-3.3	0.3	2.8	5.5	4.3	2.4	-6.5	4.0	-1.8	0.0
EPS EPS₹	3.6	-1.2	-3.0	0.0	2.4	4.0	4.5	3.4	-5.5	-18.9	1.5	-0.2

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	489	534	721	892	1,049	1,187	1,412	1,682	1,613	1,629	1,723	1,845
Growth Revenue Growth%	-12.3	9.1	35.0	23.8	17.6	13.2	18.9	19.1	-4.1	1.0	5.8	9.3
Expenses ExpensesCr	398	506	708	824	918	1,005	1,259	1,476	1,539	1,413	1,616	1,760
Operating Profit Operating ProfitCr	92	28	13	69	131	182	153	205	74	216	107	85
OPM OPM%	18.8	5.3	1.7	7.7	12.5	15.3	10.8	12.2	4.6	13.3	6.2	4.6
Other Income Other IncomeCr	0	15	12	14	3	5	33	-4	-34	6	5	-2
Interest Expense Interest ExpenseCr	24	27	28	37	43	38	36	59	60	96	73	73
Depreciation DepreciationCr	17	22	27	29	33	44	56	63	79	61	71	75
PBT PBTCr	50	-6	-31	17	58	105	94	80	-99	65	-32	-65
Tax TaxCr	14	-2	-7	14	28	40	34	41	6	-1	0	-1
PAT PATCr	36	-4	-24	3	30	65	60	40	-105	65	-32	1
Growth PAT Growth%	-34.9	-112.4	-440.0	112.5	892.4	119.1	-7.6	-34.1	-363.4	162.1	-148.4	100.5
NPM NPM%	7.3	-0.8	-3.3	0.3	2.8	5.5	4.3	2.4	-6.5	4.0	-1.8	0.0
EPS EPS₹	3.6	-1.2	-3.0	0.0	2.4	4.0	4.5	3.4	-5.5	-18.9	1.5	-0.2

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	10	10	12	12	12	13	16	16	17	19	19
Reserves ReservesCr	167	202	359	335	388	582	729	800	845	880	1,018
Current Liabilities Current LiabilitiesCr	280	386	471	460	548	478	595	793	732	846	974
Non Current Liabilities Non Current LiabilitiesCr	27	57	112	196	226	291	440	443	363	303	349
Total Liabilities Total LiabilitiesCr	483	673	1,017	1,087	1,234	1,482	1,800	2,060	1,952	2,024	2,324
Current Assets Current AssetsCr	300	419	666	672	675	795	894	1,088	1,001	1,183	1,234
Non Current Assets Non Current AssetsCr	183	253	351	414	559	687	907	972	951	840	1,090
Total Assets Total AssetsCr	483	673	1,017	1,087	1,234	1,482	1,800	2,060	1,952	2,024	2,324

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	10	10	12	12	12	13	16	16	17	19	19
Reserves ReservesCr	167	202	359	335	388	582	729	800	845	880	1,018
Current Liabilities Current LiabilitiesCr	280	386	471	460	548	478	595	793	732	846	974
Non Current Liabilities Non Current LiabilitiesCr	27	57	112	196	226	291	440	443	363	303	349
Total Liabilities Total LiabilitiesCr	483	673	1,017	1,087	1,234	1,482	1,800	2,060	1,952	2,024	2,324
Current Assets Current AssetsCr	300	419	666	672	675	795	894	1,088	1,001	1,183	1,234
Non Current Assets Non Current AssetsCr	183	253	351	414	559	687	907	972	951	840	1,090
Total Assets Total AssetsCr	483	673	1,017	1,087	1,234	1,482	1,800	2,060	1,952	2,024	2,324

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	72	-9	-15	-9	86	117	145	51	139	23	82
Investing Cash Flow Investing Cash FlowCr	-66	-83	-149	-2	-90	-133	-249	-125	-67	-75	-53
Financing Cash Flow Financing Cash FlowCr	-7	91	182	26	3	39	136	60	-86	76	-25
Net Cash Flow Net Cash FlowCr	-1	-1	18	15	-1	23	32	-14	-13	24	4
Free Cash Flow Free Cash FlowCr	5	-39	-34	-78	-48	34	-68	-93	79	-19	20
CFO To PAT CFO To PAT%	199.8	195.8	64.3	-299.3	288.4	179.6	240.9	127.8	-132.5	35.3	-260.3
CFO To EBITDA CFO To EBITDA%	78.0	-30.9	-122.8	-13.1	65.8	64.5	95.2	24.8	188.0	10.6	76.8

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	72	-9	-15	-9	86	117	145	51	139	23	82
Investing Cash Flow Investing Cash FlowCr	-66	-83	-149	-2	-90	-133	-249	-125	-67	-75	-53
Financing Cash Flow Financing Cash FlowCr	-7	91	182	26	3	39	136	60	-86	76	-25
Net Cash Flow Net Cash FlowCr	-1	-1	18	15	-1	23	32	-14	-13	24	4
Free Cash Flow Free Cash FlowCr	5	-39	-34	-78	-48	34	-68	-93	79	-19	20
CFO To PAT CFO To PAT%	199.8	195.8	64.3	-299.3	288.4	179.6	240.9	127.8	-132.5	35.3	-260.3
CFO To EBITDA CFO To EBITDA%	78.0	-30.9	-122.8	-13.1	65.8	64.5	95.2	24.8	188.0	10.6	76.8

Consolidated

Standalone

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	855	927	1,235	604	478	1,782	2,190	2,001	1,495	3,155	1,862	1,751
Price To Earnings Price To Earnings	24.5			997.0	15.8	35.0	36.0	38.4	-16.1		67.3
Price To Sales Price To Sales	1.8	1.7	1.7	0.7	0.5	1.5	1.6	1.2	1.0	1.9	1.1	0.9
Price To Book Price To Book	4.8	4.4	3.3	1.7	1.2	3.6	3.3	2.7	1.8	3.5	1.8	1.7
EV To EBITDA EV To EBITDA	10.9	43.2	123.0	13.7	7.0	11.8	17.6	13.2	28.2	16.9	22.7	28.2
Profitability Ratios Profitability Ratios
GPM GPM%	41.7	36.7	28.0	32.2	36.6	38.7	28.6	30.1	25.0	32.9	30.0	30.0
OPM OPM%	18.8	5.3	1.7	7.7	12.5	15.3	10.8	12.2	4.6	13.3	6.2	4.6
NPM NPM%	7.3	-0.8	-3.3	0.3	2.8	5.5	4.3	2.4	-6.5	4.0	-1.8	0.0
ROCE ROCE%	21.7	3.9	-0.3	6.8	11.2	13.0	9.3	8.6	-2.5	10.4	2.3	2.3
ROE ROE%	20.3	-2.1	-6.5	0.9	7.5	11.0	8.1	4.9	-12.2	7.3	-3.0	-3.0
ROA ROA%	7.4	-0.7	-2.4	0.3	2.4	4.4	3.4	1.9	-5.4	3.2	-1.4	-1.4
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	855	927	1,235	604	478	1,782	2,190	2,001	1,495	3,155	1,862	1,751
Price To Earnings Price To Earnings	24.5			997.0	15.8	35.0	36.0	38.4	-16.1		67.3
Price To Sales Price To Sales	1.8	1.7	1.7	0.7	0.5	1.5	1.6	1.2	1.0	1.9	1.1	0.9
Price To Book Price To Book	4.8	4.4	3.3	1.7	1.2	3.6	3.3	2.7	1.8	3.5	1.8	1.7
EV To EBITDA EV To EBITDA	10.9	43.2	123.0	13.7	7.0	11.8	17.6	13.2	28.2	16.9	22.7	28.2
Profitability Ratios Profitability Ratios
GPM GPM%	41.7	36.7	28.0	32.2	36.6	38.7	28.6	30.1	25.0	32.9	30.0	30.0
OPM OPM%	18.8	5.3	1.7	7.7	12.5	15.3	10.8	12.2	4.6	13.3	6.2	4.6
NPM NPM%	7.3	-0.8	-3.3	0.3	2.8	5.5	4.3	2.4	-6.5	4.0	-1.8	0.0
ROCE ROCE%	21.7	3.9	-0.3	6.8	11.2	13.0	9.3	8.6	-2.5	10.4	2.3	2.3
ROE ROE%	20.3	-2.1	-6.5	0.9	7.5	11.0	8.1	4.9	-12.2	7.3	-3.0	-3.0
ROA ROA%	7.4	-0.7	-2.4	0.3	2.4	4.4	3.4	1.9	-5.4	3.2	-1.4	-1.4
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

	SHK	CAMLINFINE	SHREEPUSHK	PCCL	HOCL	ARCL
Market CapitalizationMkt CapCr	1,869	1,751	1,671	1,087	360	182
Close PriceClose₹	135.00	91.14	516.80	440.00	53.55	228.05
IndustryIndustry	Chemicals Others	Chemicals Others	Chemicals Others	Chemicals Others	Chemicals Others	Chemicals Others
Price To EarningsPE	21.00		23.19	42.39		17.68
Price To SalesPS	0.76	0.95	1.67	1.88	0.71	0.67
RevenueRevenueCr	2,450	1,845	1,002	577	506	272
Revenue Growth TTMRev Gr TTM%	9.7%	9.3%	15.7%	94.8%	-21.0%	5.4%
PAT Growth TTMPAT Gr TTM%	-52.0%	100.5%	8.0%	168.7%	-100.6%	-23.9%

	SHK	CAMLINFINE	SHREEPUSHK	PCCL	HOCL	ARCL
Market CapitalizationMkt CapCr	1,869	1,751	1,671	1,087	360	182
Close PriceClose₹	135.00	91.14	516.80	440.00	53.55	228.05
IndustryIndustry	Chemicals Others	Chemicals Others	Chemicals Others	Chemicals Others	Chemicals Others	Chemicals Others
Price To EarningsPE	21.00		23.19	42.39		17.68
Price To SalesPS	0.76	0.95	1.67	1.88	0.71	0.67
RevenueRevenueCr	2,450	1,845	1,002	577	506	272
Revenue Growth TTMRev Gr TTM%	9.7%	9.3%	15.7%	94.8%	-21.0%	5.4%
PAT Growth TTMPAT Gr TTM%	-52.0%	100.5%	8.0%	168.7%	-100.6%	-23.9%

FY2026

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2026

Jun 26